Barrier For Applying AI To Precision Medicine: Drug Industry Reluctance To Share Data
Eric Topol says there is not enough regulatory teeth to require companies to share data with the medical community. Experts at a workshop on the application of artificial intelligence and machine learning for precision medicine also want data and algorithms to be accessible.
You may also be interested in...
Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics
Center for Drug Evaluation and Research plans to issue a request for information this year to engage stakeholders on issues related to AI and machine learning. It received 175 AI/ML submissions in 2022, up from 14 in 2020.
The pace of artificial intelligence development has accelerated in recent years and now most of the artificial intelligence devices approved by the FDA are imaging devices.